MBCQ
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
MBCQ is a cGMP-specific phosphodiesterase PDE5 inhibitor.
The phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is an agent used to inhibit the degradative action of cGMP-specific PDE5 on cyclic GMP in the smooth muscle cells lining the blood vessels supplying the corpus cavernosum of the penis. PDE5 drugs are used in the treatment of erectile dysfunction and were the first effective oral treatment for this condition. Sinve PDE5 is also present in the arterial wall smooth muscle within the lungs, PDE5 inhibitors have also been applied for the pulmonary hypertension treatment.
In vitro: In previous study, it was found that the addition of MBCQ to the blood vessle samples could lead to an 80 to 85% inhibition of PDE activity, indicating that most of the activity present in these blood vessels could be attributed to PDE5. [1].
In vivo: In animal rat study, tolerance was induced by continuous exposure to glyceryl trinitrate (GTN) for 48 h. Results showed that MBCQ could significantly decrease the EC(50) values for GTN-induced relaxation in both tolerant and nontolerant tissues, but with the greatest relative shift showing in tolerant veins. Moreover, MBCQ could also increase the vasodilator potency of a nitric oxide donor (1,1-diethyl-2-hydroxy-2-nitrosohydrazine). A significant increase in cGMP PDE activity was found in tolerant femoral vein, whereas PDE activity was unchanged in femoral artery [1].
Clinical trial: Up to now, MBCQ is still in the preclinical development stage.
Reference:
[1] MacPherson JD, Gillespie TD, Dunkerley HA, Maurice DH, Bennett BM. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation. J Pharmacol Exp Ther. 2006 Apr;317(1):188-95.
Storage | Store at -20°C |
M.Wt | 313.7 |
Cas No. | 150450-53-6 |
Formula | C16H12ClN3O2 |
Solubility | Soluble in DMSO |
Chemical Name | N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine |
SDF | Download SDF |
Canonical SMILES | ClC1=CC2=C(C=C1)N=CN=C2NCC3=CC(OCO4)=C4C=C3 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |